Portage Biotech Highlights Promising Data Presented on STING-Activating Therapy, PORT-5 (STI-001) at AACR 2022 Annual Meeting
April 13, 2022 10:00 ET
|
Portage Biotech Inc.
WESTPORT, Conn., April 13, 2022 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”), a clinical-stage immuno-oncology company developing therapies to improve...
Portage Biotech Announces Financial Results and Provides Business Update for Second Quarter of 2022 Fiscal Year
November 23, 2021 08:00 ET
|
Portage Biotech Inc.
Initiated PORT-2 Phase 1/2 IMP-MEL trial in patients with Melanoma & NSCLCEnrollment ongoing in Phase 1 PRECIOUS-01 study of PORT-3 for the treatment of NY-ESO-1 positive solid tumors WESTPORT,...
Portage Biotech Issues Letter to Shareholders
August 12, 2021 08:00 ET
|
Portage Biotech Inc.
WESTPORT, Conn., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Portage Biotech Inc., (NASDAQ: PRTG) (“Portage” or the “Company”) a clinical-stage immuno-oncology company focused on the development of therapies...
Portage Biotech Announces Results for Fiscal Year Ended March 31, 2021
July 28, 2021 08:00 ET
|
Portage Biotech Inc.
- Transformative year included multiple corporate, clinical, and financial milestones, positioning Portage to accelerate development of first-in-class immuno-oncology assets- Additional clinical...